(Q43151297)

14 November 2017

0 references

Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease (English)

1 reference

14 November 2017

1

Charles A Dinarello

1 reference

14 November 2017

PMCID

2664579

language of work or name

English

0 references

publication date

1 February 2009

1 reference

14 November 2017

1 reference

14 November 2017

84

1 reference

14 November 2017

2

1 reference

14 November 2017

105-107

1 reference

Immunological and inflammatory functions of the interleukin-1 family

14 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

IL-1 is required for tumor invasiveness and angiogenesis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

The role of interleukin-1 beta in the pathogenesis of multiple myeloma

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2664579

Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors

1 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19181642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19181642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19181642

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4065/84.2.105

1 reference

14 November 2017

1 reference

14 November 2017

1 reference

PMCID

2664579